The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer

Antzeko izenburuak

• Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer
  nork: Lamberti, Giuseppe, et al.
  Argitaratua: (2019)
• The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
  nork: Gao, Xin, et al.
  Argitaratua: (2016)
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  nork: Mok, T.S., et al.
  Argitaratua: (2016)
• Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
  nork: Nanjo, Shigeki, et al.
  Argitaratua: (2018)
• EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
  nork: Zheng, Qiufan, et al.
  Argitaratua: (2020)